Please login to the form below

Not currently logged in
Email:
Password:

Cancer Drug Fund

This page shows the latest Cancer Drug Fund news and features for those working in and with pharma, biotech and healthcare.

Keytruda achieves cost effectiveness milestone, first to exit Cancer Drugs Fund

Keytruda achieves cost effectiveness milestone, first to exit Cancer Drugs Fund

This means it will now be removed from the ‘managed access’Cancer Drugs Fund (CDF) the first drug to achieve this since the remodelled system was launched two years ago. ... It’s nearest competitor in front line NSCLC treatment is Tecentriq,

Latest news

  • NICE U-turn on Opdivo for kidney cancer NICE U-turn on Opdivo for kidney cancer

    guidance. Opdivo (nivolumab) is now set to be recommended as a second-line treatment on the NHS in England and Wales almost immediately as the Cancer Drugs Fund will support the ... happy that NICE has made this recommendation for patients with advanced

  • Reformed Cancer Drugs Fund backs its first drug - AZ’s Tagrisso Reformed Cancer Drugs Fund backs its first drug - AZ’s Tagrisso

    Reformed Cancer Drugs Fund backs its first drug - AZ’ s Tagrisso. ... AstraZeneca's Tagrisso (osimertinib) has become the first drug to be supported by the UK's newly-reformed Cancer Drugs Fund (CDF).

  • Pfizer warns against price-cutting after NICE backs Bosulif Pfizer warns against price-cutting after NICE backs Bosulif

    Pfizer warns against price-cutting after NICE backs Bosulif. Cancer drug is the first to be re-appraised form the CDF. ... NICE has approved the first re-appraised drug from the now-defunct Cancer Drugs Fund (CDF) - but Pfizer has warned that companies

  • Imbruvica wins wider European leukaemia licence Imbruvica wins wider European leukaemia licence

    AbbVie and Johnson &Johnson have been granted a European licence for the expanded use of their chemotherapy alternative drug Imbruvica. ... Despite Imbruvica's status as the most requested CLL drug available on the Cancer Drugs Fund (CDF), the

  • NICE changes tack on Sanofi's prostate cancer drug Jevtana NICE changes tack on Sanofi's prostate cancer drug Jevtana

    NICE changes tack on Sanofi's prostate cancer drug Jevtana. Approves the therapy for NHS use after accepting undisclosed additional discount. ... This important drug can offer precious extra time to men who are dealing with the latter stages of prostate

More from news
Approximately 1 fully matching, plus 27 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics